Next Generation Therapeutics
for Mental Health Disorders

Activating Brain Plasticity Through Novel Molecules
to Overcome the Limitations of Existing Therapies
Our goal is to lead the development of combination therapies that enhance neuroplasticity and improve psychiatric outcomes.
Once daily oral dosage form
No supervision
Designed for efficacy with minimal side effects

No interruption to daily lifestyle

Transforming mental health

Our lead drug candidate is a fixed-dose combination of an SSRI and a micro-dose of ibogaine – a central nervous system stimulant.

Unleashing the therapeutic
potential of Ibogaine

IBOGAINE

Ibogaine is a powerful compound derived from the root bark of the iboga tree (Tabernanthe iboga), native to Central and West Africa.

Historically, it was marketed in France until the 1970s under the name Lambarène as a stimulant.

Today, ibogaine is at the forefront of cutting-edge research in the United States, being developed not only as a promising treatment for addiction but also for its potential to revolutionize depression therapy by enhancing neuroplasticity and addressing treatment-resistant cases.

Leveraging existing know-how and technology

Management

Itay Hecht
Business Development
Itay is an entrepreneur with vast experience in the private and public sectors. He oversaw the first IPO of medical Cannabis company in the Tel Aviv Stock Exchange. Prior to PsyRx Itay served as the CEO of Hi-Pharma Ltd, a medical cannabis company for 2 years and 7 years as COO of Palgi Sharon - Israeli Municipal Water Corporation.
Moshe Neuman, PhD
Regulatory Affairs

Board of Directors

Itamar Grotto
Executive Chairman
Asher Holtzer
CCO & Co Founder
Kobi Buxdorf
CTO & Co Founder
Itay Hecht
Biz Dev& Co Founder
Maggie Levy
Dany Zadok





    Skip to content